Comparative polymyxin B pharmacokinetics in patients receiving extracorporeal membrane oxygenation
Journal of Antimicrobial Chemotherapy2022Vol. 77(5), pp. 1379–1384
Citations Over TimeTop 11% of 2022 papers
Yury A. Surovoy, Maksim A. Burkin, Inna A. Galvidis, П. О. Бочков, Armen V. Oganesyan, С. В. Царенко
Abstract
Currently recommended polymyxin B dosage regimens are sufficient for patients receiving ECMO and no dosage increase is required. In our study, polymyxin B exposure was higher in ECMO patients compared with the control group.
Related Papers
- → Increased extracorporeal membrane oxygenation center case volume is associated with improved extracorporeal membrane oxygenation survival among pediatric patients(2012)170 cited
- → A novel approach to the management of critically ill neonatal Ebstein′s anomaly: Veno-venous extracorporeal membrane oxygenation to promote right ventricular recovery(2015)10 cited
- → Eighteen years of paediatric extracorporeal membrane oxygenation and ventricular assist devices: insight regarding late outcomes(2018)4 cited
- → Intracranial abnormalities and neurodevelopmental status after venovenous extracorporeal membrane oxygenation(1994)14 cited
- → M38 Duration of Extracorporeal Membrane Oxygenation Support Does Not Correlate With Survival(2021)